{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:11:23Z","timestamp":1790705483744,"version":"4.1.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neuropathol"],"DOI":"10.1007\/s00401-025-02872-9","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T07:25:38Z","timestamp":1746170738000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Widespread distribution of \u03b1-synuclein oligomers in LRRK2-related Parkinson\u2019s disease"],"prefix":"10.1007","volume":"149","author":[{"given":"Hiroaki","family":"Sekiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Franke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Takata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuya","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naonobu","family":"Futamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuko","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisatomo","family":"Kowa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen A.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela J.","family":"McLean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsushi","family":"Toda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zbigniew K.","family":"Wszolek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis W.","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,2]]},"reference":[{"key":"2872_CR1","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3389\/fnagi.2014.00248","volume":"6","author":"JO Aasly","year":"2014","unstructured":"Aasly JO, Johansen KK, Br\u00f8nstad G, War\u00f8 BJ, Majbour NK, Varghese S et al (2014) Elevated levels of cerebrospinal fluid \u03b1-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers. Front Aging Neurosci 6:248. https:\/\/doi.org\/10.3389\/fnagi.2014.00248","journal-title":"Front Aging Neurosci"},{"key":"2872_CR2","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1002\/mds.29449","volume":"38","author":"J Agin-Liebes","year":"2023","unstructured":"Agin-Liebes J, Hickman RA, Vonsattel JP, Faust PL, Flowers X, Utkina Sosunova I et al (2023) Patterns of TDP-43 deposition in brains with LRRK2 G2019S mutations. Mov Disord 38:1541\u20131545. https:\/\/doi.org\/10.1002\/mds.29449","journal-title":"Mov Disord"},{"key":"2872_CR3","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1146\/annurev-biochem-030122-051144","volume":"93","author":"DR Alessi","year":"2024","unstructured":"Alessi DR, Pfeffer SR (2024) Leucine-rich repeat kinases. Annu Rev Biochem 93:261\u2013287. https:\/\/doi.org\/10.1146\/annurev-biochem-030122-051144","journal-title":"Annu Rev Biochem"},{"key":"2872_CR4","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s00401-013-1188-4","volume":"126","author":"RM Bailey","year":"2013","unstructured":"Bailey RM, Covy JP, Melrose HL, Rousseau L, Watkinson R, Knight J et al (2013) LRRK2 phosphorylates novel tau epitopes and promotes tauopathy. Acta Neuropathol 126:809\u2013827. https:\/\/doi.org\/10.1007\/s00401-013-1188-4","journal-title":"Acta Neuropathol"},{"key":"2872_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.104782","volume":"137","author":"S Bandres-Ciga","year":"2020","unstructured":"Bandres-Ciga S, Diez-Fairen M, Kim JJ, Singleton AB (2020) Genetics of Parkinson\u2019s disease: an introspection of its journey towards precision medicine. Neurobiol Dis 137:104782. https:\/\/doi.org\/10.1016\/j.nbd.2020.104782","journal-title":"Neurobiol Dis"},{"key":"2872_CR6","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1002\/jnr.24927","volume":"99","author":"A Behere","year":"2021","unstructured":"Behere A, Th\u00f6rnqvist PO, Winberg S, Ingelsson M, Bergstr\u00f6m J, Ekmark-Lew\u00e9n S (2021) Visualization of early oligomeric \u03b1-synuclein pathology and its impact on the dopaminergic system in the (Thy-1)-h[A30P]\u03b1-syn transgenic mouse model. J Neurosci Res 99:2525\u20132539. https:\/\/doi.org\/10.1002\/jnr.24927","journal-title":"J Neurosci Res"},{"key":"2872_CR7","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1212\/wnl.0000000000200878","volume":"99","author":"G Bellomo","year":"2022","unstructured":"Bellomo G, De Luca CMG, Paoletti FP, Gaetani L, Moda F, Parnetti L (2022) \u03b1-Synuclein seed amplification assays for diagnosing synucleinopathies: the way forward. Neurology 99:195\u2013205. https:\/\/doi.org\/10.1212\/wnl.0000000000200878","journal-title":"Neurology"},{"key":"2872_CR8","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s00401-019-01995-0","volume":"137","author":"G Bieri","year":"2019","unstructured":"Bieri G, Brahic M, Bousset L, Couthouis J, Kramer NJ, Ma R et al (2019) LRRK2 modifies \u03b1-syn pathology and spread in mouse models and human neurons. Acta Neuropathol 137:961\u2013980. https:\/\/doi.org\/10.1007\/s00401-019-01995-0","journal-title":"Acta Neuropathol"},{"key":"2872_CR9","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/s1474-4422(19)30287-x","volume":"19","author":"C Blauwendraat","year":"2020","unstructured":"Blauwendraat C, Nalls MA, Singleton AB (2020) The genetic architecture of Parkinson\u2019s disease. Lancet Neurol 19:170\u2013178. https:\/\/doi.org\/10.1016\/s1474-4422(19)30287-x","journal-title":"Lancet Neurol"},{"key":"2872_CR10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/bf00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239\u2013259. https:\/\/doi.org\/10.1007\/bf00308809","journal-title":"Acta Neuropathol"},{"key":"2872_CR11","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/s0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak H, Del Tredici K, R\u00fcb U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol Aging 24:197\u2013211. https:\/\/doi.org\/10.1016\/s0197-4580(02)00065-9","journal-title":"Neurobiol Aging"},{"key":"2872_CR12","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1016\/j.neurobiolaging.2011.11.002","volume":"33","author":"S Chiba","year":"2012","unstructured":"Chiba S, Takada E, Tadokoro M, Taniguchi T, Kadoyama K, Takenokuchi M et al (2012) Loss of dopaminoreceptive neuron causes L-dopa resistant parkinsonism in tauopathy. Neurobiol Aging 33:2491\u20132505. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2011.11.002","journal-title":"Neurobiol Aging"},{"key":"2872_CR13","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.cell.2012.03.037","volume":"149","author":"N Cremades","year":"2012","unstructured":"Cremades N, Cohen SI, Deas E, Abramov AY, Chen AY, Orte A et al (2012) Direct observation of the interconversion of normal and toxic forms of \u03b1-synuclein. Cell 149:1048\u20131059. https:\/\/doi.org\/10.1016\/j.cell.2012.03.037","journal-title":"Cell"},{"key":"2872_CR14","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1093\/hmg\/dds057","volume":"21","author":"JP Daher","year":"2012","unstructured":"Daher JP, Pletnikova O, Biskup S, Musso A, Gellhaar S, Galter D et al (2012) Neurodegenerative phenotypes in an A53T \u03b1-synuclein transgenic mouse model are independent of LRRK2. Hum Mol Genet 21:2420\u20132431. https:\/\/doi.org\/10.1093\/hmg\/dds057","journal-title":"Hum Mol Genet"},{"key":"2872_CR15","doi-asserted-by":"publisher","first-page":"9289","DOI":"10.1073\/pnas.1403215111","volume":"111","author":"JP Daher","year":"2014","unstructured":"Daher JP, Volpicelli-Daley LA, Blackburn JP, Moehle MS, West AB (2014) Abrogation of \u03b1-synuclein-mediated dopaminergic neurodegeneration in LRRK2-deficient rats. Proc Natl Acad Sci U S A 111:9289\u20139294. https:\/\/doi.org\/10.1073\/pnas.1403215111","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2872_CR16","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a009258","author":"DW Dickson","year":"2012","unstructured":"Dickson DW (2012) Parkinson\u2019s disease and parkinsonism: neuropathology. Cold Spring Harb Perspect Med. https:\/\/doi.org\/10.1101\/cshperspect.a009258","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2872_CR17","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/s1474-4422(09)70238-8","volume":"8","author":"DW Dickson","year":"2009","unstructured":"Dickson DW, Braak H, Duda JE, Duyckaerts C, Gasser T, Halliday GM et al (2009) Neuropathological assessment of Parkinson\u2019s disease: refining the diagnostic criteria. Lancet Neurol 8:1150\u20131157. https:\/\/doi.org\/10.1016\/s1474-4422(09)70238-8","journal-title":"Lancet Neurol"},{"key":"2872_CR18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.5603\/pjnns.97806","volume":"58","author":"J Dulski","year":"2024","unstructured":"Dulski J, Ross OA, Wszolek ZK (2024) Genetics of Parkinson\u2019s disease: state-of-the-art and role in clinical settings. Neurol Neurochir Pol 58:38\u201346. https:\/\/doi.org\/10.5603\/pjnns.97806","journal-title":"Neurol Neurochir Pol"},{"key":"2872_CR19","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1096\/fj.03-1449com","volume":"20","author":"OM El-Agnaf","year":"2006","unstructured":"El-Agnaf OM, Salem SA, Paleologou KE, Curran MD, Gibson MJ, Court JA et al (2006) Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson\u2019s disease. Faseb J 20:419\u2013425. https:\/\/doi.org\/10.1096\/fj.03-1449com","journal-title":"Faseb J"},{"key":"2872_CR20","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/ana.10113","volume":"51","author":"M Funayama","year":"2002","unstructured":"Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji S, Obata F (2002) A new locus for Parkinson\u2019s disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol 51:296\u2013301. https:\/\/doi.org\/10.1002\/ana.10113","journal-title":"Ann Neurol"},{"key":"2872_CR21","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/ana.20484","volume":"57","author":"M Funayama","year":"2005","unstructured":"Funayama M, Hasegawa K, Ohta E, Kawashima N, Komiyama M, Kowa H et al (2005) An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann Neurol 57:918\u2013921. https:\/\/doi.org\/10.1002\/ana.20484","journal-title":"Ann Neurol"},{"key":"2872_CR22","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s10038-022-01058-5","volume":"68","author":"M Funayama","year":"2023","unstructured":"Funayama M, Nishioka K, Li Y, Hattori N (2023) Molecular genetics of Parkinson\u2019s disease: Contributions and global trends. J Hum Genet 68:125\u2013130. https:\/\/doi.org\/10.1038\/s10038-022-01058-5","journal-title":"J Hum Genet"},{"key":"2872_CR23","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/(sici)1097-4547(20000215)59:4<528::Aid-jnr8>3.0.Co;2-0","volume":"59","author":"BI Giasson","year":"2000","unstructured":"Giasson BI, Jakes R, Goedert M, Duda JE, Leight S, Trojanowski JQ et al (2000) A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson\u2019s disease. J Neurosci Res 59:528\u2013533. https:\/\/doi.org\/10.1002\/(sici)1097-4547(20000215)59:4%3c528::Aid-jnr8%3e3.0.Co;2-0","journal-title":"J Neurosci Res"},{"key":"2872_CR24","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1093\/hmg\/ddi439","volume":"15","author":"CJ Gloeckner","year":"2006","unstructured":"Gloeckner CJ, Kinkl N, Schumacher A, Braun RJ, O\u2019Neill E, Meitinger T et al (2006) The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet 15:223\u2013232. https:\/\/doi.org\/10.1093\/hmg\/ddi439","journal-title":"Hum Mol Genet"},{"key":"2872_CR25","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.parkreldis.2008.07.010","volume":"15","author":"K Hasegawa","year":"2009","unstructured":"Hasegawa K, Stoessl AJ, Yokoyama T, Kowa H, Wszolek ZK, Yagishita S (2009) Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes. Parkinsonism Relat Disord 15:300\u2013306. https:\/\/doi.org\/10.1016\/j.parkreldis.2008.07.010","journal-title":"Parkinsonism Relat Disord"},{"key":"2872_CR26","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1212\/01.wnl.0000304044.22253.03","volume":"70","author":"K Haugarvoll","year":"2008","unstructured":"Haugarvoll K, Rademakers R, Kachergus JM, Nuytemans K, Ross OA, Gibson JM et al (2008) Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. Neurology 70:1456\u20131460. https:\/\/doi.org\/10.1212\/01.wnl.0000304044.22253.03","journal-title":"Neurology"},{"key":"2872_CR27","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/s1474-4422(08)70117-0","volume":"7","author":"DG Healy","year":"2008","unstructured":"Healy DG, Falchi M, O\u2019Sullivan SS, Bonifati V, Durr A, Bressman S et al (2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson\u2019s disease: a case-control study. Lancet Neurol 7:583\u2013590. https:\/\/doi.org\/10.1016\/s1474-4422(08)70117-0","journal-title":"Lancet Neurol"},{"key":"2872_CR28","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s40478-019-0836-x","volume":"7","author":"MX Henderson","year":"2019","unstructured":"Henderson MX, Sengupta M, Trojanowski JQ, Lee VMY (2019) Alzheimer\u2019s disease tau is a prominent pathology in LRRK2 Parkinson\u2019s disease. Acta Neuropathol Commun 7:183. https:\/\/doi.org\/10.1186\/s40478-019-0836-x","journal-title":"Acta Neuropathol Commun"},{"key":"2872_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0036581","volume":"7","author":"MC Herzig","year":"2012","unstructured":"Herzig MC, Bidinosti M, Schweizer T, Hafner T, Stemmelen C, Weiss A et al (2012) High LRRK2 levels fail to induce or exacerbate neuronal alpha-synucleinopathy in mouse brain. PLoS ONE 7:e36581. https:\/\/doi.org\/10.1371\/journal.pone.0036581","journal-title":"PLoS ONE"},{"key":"2872_CR30","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41531-022-00386-9","volume":"8","author":"PW Ho","year":"2022","unstructured":"Ho PW, Chang EE, Leung CT, Liu H, Malki Y, Pang SY et al (2022) Long-term inhibition of mutant LRRK2 hyper-kinase activity reduced mouse brain \u03b1-synuclein oligomers without adverse effects. NPJ Parkinsons Dis 8:115. https:\/\/doi.org\/10.1038\/s41531-022-00386-9","journal-title":"NPJ Parkinsons Dis"},{"key":"2872_CR31","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1042\/bj20070209","volume":"405","author":"M Jaleel","year":"2007","unstructured":"Jaleel M, Nichols RJ, Deak M, Campbell DG, Gillardon F, Knebel A et al (2007) LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson\u2019s disease mutants affect kinase activity. Biochem J 405:307\u2013317. https:\/\/doi.org\/10.1042\/bj20070209","journal-title":"Biochem J"},{"key":"2872_CR32","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1001\/jamaneurol.2014.2704","volume":"72","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE, Hazrati LN, Fujioka S, Wszolek ZK, Dickson DW et al (2015) Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. JAMA Neurol 72:100\u2013105. https:\/\/doi.org\/10.1001\/jamaneurol.2014.2704","journal-title":"JAMA Neurol"},{"key":"2872_CR33","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13024-021-00501-z","volume":"16","author":"S Koga","year":"2021","unstructured":"Koga S, Sekiya H, Kondru N, Ross OA, Dickson DW (2021) Neuropathology and molecular diagnosis of synucleinopathies. Mol Neurodegener 16:83. https:\/\/doi.org\/10.1186\/s13024-021-00501-z","journal-title":"Mol Neurodegener"},{"key":"2872_CR34","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2307\/2529310","volume":"33","author":"JR Landis","year":"1977","unstructured":"Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159\u2013174","journal-title":"Biometrics"},{"key":"2872_CR35","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s00401-024-02781-3","volume":"148","author":"RK Leak","year":"2024","unstructured":"Leak RK, Clark RN, Abbas M, Xu F, Brodsky JL, Chen J et al (2024) Current insights and assumptions on \u03b1-synuclein in Lewy body disease. Acta Neuropathol 148:18. https:\/\/doi.org\/10.1007\/s00401-024-02781-3","journal-title":"Acta Neuropathol"},{"key":"2872_CR36","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.neuron.2009.11.006","volume":"64","author":"X Lin","year":"2009","unstructured":"Lin X, Parisiadou L, Gu XL, Wang L, Shim H, Sun L et al (2009) Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson\u2019s-disease-related mutant alpha-synuclein. Neuron 64:807\u2013827. https:\/\/doi.org\/10.1016\/j.neuron.2009.11.006","journal-title":"Neuron"},{"key":"2872_CR37","doi-asserted-by":"publisher","first-page":"2889.e2885","DOI":"10.1016\/j.neurobiolaging.2013.04.011","volume":"34","author":"H Ling","year":"2013","unstructured":"Ling H, Kara E, Bandopadhyay R, Hardy J, Holton J, Xiromerisiou G et al (2013) TDP-43 pathology in a patient carrying G2019S LRRK2 mutation and a novel p. Q124E MAPT. Neurobiol Aging 34:2889.e2885-2889. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2013.04.011","journal-title":"Neurobiol Aging"},{"key":"2872_CR38","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40035-020-00192-4","volume":"9","author":"NK Majbour","year":"2020","unstructured":"Majbour NK, Aasly JO, Hustad E, Thomas MA, Vaikath NN, Elkum N et al (2020) CSF total and oligomeric \u03b1-Synuclein along with TNF-\u03b1 as risk biomarkers for Parkinson\u2019s disease: a study in LRRK2 mutation carriers. Transl Neurodegener 9:15. https:\/\/doi.org\/10.1186\/s40035-020-00192-4","journal-title":"Transl Neurodegener"},{"key":"2872_CR39","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1212\/WNL.0b013e318227042d","volume":"77","author":"C Marras","year":"2011","unstructured":"Marras C, Sch\u00fcle B, Munhoz RP, Rogaeva E, Langston JW, Kasten M et al (2011) Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers. Neurology 77:325\u2013333. https:\/\/doi.org\/10.1212\/WNL.0b013e318227042d","journal-title":"Neurology"},{"key":"2872_CR40","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1093\/brain\/awaa126","volume":"143","author":"Y Miki","year":"2020","unstructured":"Miki Y, Foti SC, Hansen D, Strand KM, Asi YT, Tsushima E et al (2020) Hippocampal \u03b1-synuclein pathology correlates with memory impairment in multiple system atrophy. Brain 143:1798\u20131810. https:\/\/doi.org\/10.1093\/brain\/awaa126","journal-title":"Brain"},{"key":"2872_CR41","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1136\/jnnp-2017-316864","volume":"89","author":"T Mishima","year":"2018","unstructured":"Mishima T, Fujioka S, Tomiyama H, Yabe I, Kurisaki R, Fujii N et al (2018) Establishing diagnostic criteria for Perry syndrome. J Neurol Neurosurg Psychiatry 89:482\u2013487. https:\/\/doi.org\/10.1136\/jnnp-2017-316864","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2872_CR42","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.13100","author":"A Murakami","year":"2022","unstructured":"Murakami A, Koga S, Sekiya H, Oskarsson B, Boylan K, Petrucelli L et al (2022) Old age amyotrophic lateral sclerosis and limbic TDP-43 pathology. Brain Pathol. https:\/\/doi.org\/10.1111\/bpa.13100","journal-title":"Brain Pathol"},{"key":"2872_CR43","doi-asserted-by":"publisher","first-page":"3519","DOI":"10.1016\/j.cell.2021.05.004","volume":"184","author":"A Myasnikov","year":"2021","unstructured":"Myasnikov A, Zhu H, Hixson P, Xie B, Yu K, Pitre A et al (2021) Structural analysis of the full-length human LRRK2. Cell 184:3519-3527.e3510. https:\/\/doi.org\/10.1016\/j.cell.2021.05.004","journal-title":"Cell"},{"key":"2872_CR44","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.neuron.2004.10.023","volume":"44","author":"C Pais\u00e1n-Ru\u00edz","year":"2004","unstructured":"Pais\u00e1n-Ru\u00edz C, Jain S, Evans EW, Gilks WP, Sim\u00f3n J, van der Brug M et al (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson\u2019s disease. Neuron 44:595\u2013600. https:\/\/doi.org\/10.1016\/j.neuron.2004.10.023","journal-title":"Neuron"},{"key":"2872_CR45","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W et al (2015) MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord 30:1591\u20131601. https:\/\/doi.org\/10.1002\/mds.26424","journal-title":"Mov Disord"},{"key":"2872_CR46","doi-asserted-by":"publisher","first-page":"13042","DOI":"10.1074\/jbc.M113.537811","volume":"289","author":"S Ray","year":"2014","unstructured":"Ray S, Bender S, Kang S, Lin R, Glicksman MA, Liu M (2014) The Parkinson disease-linked LRRK2 protein mutation I2020T stabilizes an active state conformation leading to increased kinase activity. J Biol Chem 289:13042\u201313053. https:\/\/doi.org\/10.1074\/jbc.M113.537811","journal-title":"J Biol Chem"},{"key":"2872_CR47","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1093\/brain\/awv040","volume":"138","author":"RF Roberts","year":"2015","unstructured":"Roberts RF, Wade-Martins R, Alegre-Abarrategui J (2015) Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson\u2019s disease brain. Brain 138:1642\u20131657. https:\/\/doi.org\/10.1093\/brain\/awv040","journal-title":"Brain"},{"key":"2872_CR48","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.tins.2021.12.002","volume":"45","author":"EM Rocha","year":"2022","unstructured":"Rocha EM, Keeney MT, Di Maio R, De Miranda BR, Greenamyre JT (2022) LRRK2 and idiopathic Parkinson\u2019s disease. Trends Neurosci 45:224\u2013236. https:\/\/doi.org\/10.1016\/j.tins.2021.12.002","journal-title":"Trends Neurosci"},{"key":"2872_CR49","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/ana.20731","volume":"59","author":"OA Ross","year":"2006","unstructured":"Ross OA, Toft M, Whittle AJ, Johnson JL, Papapetropoulos S, Mash DC et al (2006) Lrrk2 and Lewy body disease. Ann Neurol 59:388\u2013393. https:\/\/doi.org\/10.1002\/ana.20731","journal-title":"Ann Neurol"},{"key":"2872_CR50","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1002\/humu.22075","volume":"33","author":"JP Rubio","year":"2012","unstructured":"Rubio JP, Topp S, Warren L, St Jean PL, Wegmann D, Kessner D et al (2012) Deep sequencing of the LRRK2 gene in 14,002 individuals reveals evidence of purifying selection and independent origin of the p.Arg1628Pro mutation in Europe. Hum Mutat 33:1087\u20131098. https:\/\/doi.org\/10.1002\/humu.22075","journal-title":"Hum Mutat"},{"key":"2872_CR51","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/nan.12486","volume":"44","author":"C Ruffmann","year":"2018","unstructured":"Ruffmann C, Bengoa-Vergniory N, Poggiolini I, Ritchie D, Hu MT, Alegre-Abarrategui J et al (2018) Detection of alpha-synuclein conformational variants from gastro-intestinal biopsy tissue as a potential biomarker for Parkinson\u2019s disease. Neuropathol Appl Neurobiol 44:722\u2013736. https:\/\/doi.org\/10.1111\/nan.12486","journal-title":"Neuropathol Appl Neurobiol"},{"key":"2872_CR52","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.parkreldis.2021.09.009","volume":"91","author":"M Sakuwa","year":"2021","unstructured":"Sakuwa M, Adachi T, Suzuki Y, Yoshida K, Fukuda H, Miura H et al (2021) First Japanese autopsy case showing LRRK2 mutation G2019S and TDP-43 proteinopathy. Parkinsonism Relat Disord 91:85\u201387. https:\/\/doi.org\/10.1016\/j.parkreldis.2021.09.009","journal-title":"Parkinsonism Relat Disord"},{"key":"2872_CR53","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1001\/jamaneurol.2017.4019","volume":"75","author":"R Saunders-Pullman","year":"2018","unstructured":"Saunders-Pullman R, Mirelman A, Alcalay RN, Wang C, Ortega RA, Raymond D et al (2018) Progression in the LRRK2-asssociated Parkinson disease population. JAMA Neurol 75:312\u2013319. https:\/\/doi.org\/10.1001\/jamaneurol.2017.4019","journal-title":"JAMA Neurol"},{"key":"2872_CR54","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/mds.29670","volume":"39","author":"H Sekiya","year":"2024","unstructured":"Sekiya H, Koga S, Murakami A, DeTure M, Ross OA, Uitti RJ et al (2024) Frequency of comorbid pathologies and their clinical impact in multiple system atrophy. Mov Disord 39:380\u2013390. https:\/\/doi.org\/10.1002\/mds.29670","journal-title":"Mov Disord"},{"key":"2872_CR55","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s00401-019-01961-w","volume":"137","author":"H Sekiya","year":"2019","unstructured":"Sekiya H, Kowa H, Koga H, Takata M, Satake W, Futamura N et al (2019) Wide distribution of alpha-synuclein oligomers in multiple system atrophy brain detected by proximity ligation. Acta Neuropathol 137:455\u2013466. https:\/\/doi.org\/10.1007\/s00401-019-01961-w","journal-title":"Acta Neuropathol"},{"key":"2872_CR56","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s40478-022-01440-6","volume":"10","author":"H Sekiya","year":"2022","unstructured":"Sekiya H, Tsuji A, Hashimoto Y, Takata M, Koga S, Nishida K et al (2022) Discrepancy between distribution of alpha-synuclein oligomers and Lewy-related pathology in Parkinson\u2019s disease. Acta Neuropathol Commun 10:133. https:\/\/doi.org\/10.1186\/s40478-022-01440-6","journal-title":"Acta Neuropathol Commun"},{"key":"2872_CR57","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.parkreldis.2022.05.012","volume":"98","author":"C Simpson","year":"2022","unstructured":"Simpson C, Vinikoor-Imler L, Nassan FL, Shirvan J, Lally C, Dam T et al (2022) Prevalence of ten LRRK2 variants in Parkinson\u2019s disease: a comprehensive review. Parkinsonism Relat Disord 98:103\u2013113. https:\/\/doi.org\/10.1016\/j.parkreldis.2022.05.012","journal-title":"Parkinsonism Relat Disord"},{"key":"2872_CR58","doi-asserted-by":"publisher","first-page":"fcae193","DOI":"10.1093\/braincomms\/fcae193","volume":"6","author":"MT Tanaka","year":"2024","unstructured":"Tanaka MT, Miki Y, Mori F, Kon T, Furukawa T, Shimoyama S et al (2024) Intranasal administration of trehalose reduces \u03b1-synuclein oligomers and accelerates \u03b1-synuclein aggregation. Brain Commun 6:fcae193. https:\/\/doi.org\/10.1093\/braincomms\/fcae193","journal-title":"Brain Commun"},{"key":"2872_CR59","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1002\/mds.20886","volume":"21","author":"H Tomiyama","year":"2006","unstructured":"Tomiyama H, Li Y, Funayama M, Hasegawa K, Yoshino H, Kubo S et al (2006) Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson\u2019s disease patients from 18 countries. Mov Disord 21:1102\u20131108. https:\/\/doi.org\/10.1002\/mds.20886","journal-title":"Mov Disord"},{"key":"2872_CR60","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.neurobiolaging.2013.11.015","volume":"35","author":"J Trinh","year":"2014","unstructured":"Trinh J, Amouri R, Duda JE, Morley JF, Read M, Donald A et al (2014) Comparative study of Parkinson\u2019s disease and leucine-rich repeat kinase 2 p. G2019S parkinsonism. Neurobiol Aging 35:1125\u20131131. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2013.11.015","journal-title":"Neurobiol Aging"},{"key":"2872_CR61","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.parkreldis.2012.03.024","volume":"18","author":"S Ujiie","year":"2012","unstructured":"Ujiie S, Hatano T, Kubo S, Imai S, Sato S, Uchihara T et al (2012) LRRK2 I2020T mutation is associated with tau pathology. Parkinsonism Relat Disord 18:819\u2013823. https:\/\/doi.org\/10.1016\/j.parkreldis.2012.03.024","journal-title":"Parkinsonism Relat Disord"},{"key":"2872_CR62","doi-asserted-by":"publisher","first-page":"7415","DOI":"10.1523\/jneurosci.3642-15.2016","volume":"36","author":"LA Volpicelli-Daley","year":"2016","unstructured":"Volpicelli-Daley LA, Abdelmotilib H, Liu Z, Stoyka L, Daher JP, Milnerwood AJ et al (2016) G2019S-LRRK2 expression augments \u03b1-synuclein sequestration into inclusions in neurons. J Neurosci 36:7415\u20137427. https:\/\/doi.org\/10.1523\/jneurosci.3642-15.2016","journal-title":"J Neurosci"},{"key":"2872_CR63","doi-asserted-by":"publisher","first-page":"16842","DOI":"10.1073\/pnas.0507360102","volume":"102","author":"AB West","year":"2005","unstructured":"West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA et al (2005) Parkinson\u2019s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A 102:16842\u201316847. https:\/\/doi.org\/10.1073\/pnas.0507360102","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2872_CR64","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.1073\/pnas.1100976108","volume":"108","author":"B Winner","year":"2011","unstructured":"Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S et al (2011) In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A 108:4194\u20134199. https:\/\/doi.org\/10.1073\/pnas.1100976108","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2872_CR65","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1212\/wnl.45.3.502","volume":"45","author":"ZK Wszolek","year":"1995","unstructured":"Wszolek ZK, Pfeiffer B, Fulgham JR, Parisi JE, Thompson BM, Uitti RJ et al (1995) Western Nebraska family (family D) with autosomal dominant parkinsonism. Neurology 45:502\u2013505. https:\/\/doi.org\/10.1212\/wnl.45.3.502","journal-title":"Neurology"},{"key":"2872_CR66","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1212\/01.wnl.0000125015.06989.db","volume":"62","author":"ZK Wszolek","year":"2004","unstructured":"Wszolek ZK, Pfeiffer RF, Tsuboi Y, Uitti RJ, McComb RD, Stoessl AJ et al (2004) Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology 62:1619\u20131622. https:\/\/doi.org\/10.1212\/01.wnl.0000125015.06989.db","journal-title":"Neurology"},{"key":"2872_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2024.07.004","author":"H Yamaguchi","year":"2024","unstructured":"Yamaguchi H, Nishimura Y, Matsuse D, Sekiya H, Masaki K, Tanaka T et al (2024) A rapidly progressive multiple system atrophy-cerebellar variant model presenting marked glial reactions with inflammation and spreading of \u03b1-synuclein oligomers and phosphorylated \u03b1-synuclein aggregates. Brain Behav Immun. https:\/\/doi.org\/10.1016\/j.bbi.2024.07.004","journal-title":"Brain Behav Immun"},{"key":"2872_CR68","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.neuron.2004.11.005","volume":"44","author":"A Zimprich","year":"2004","unstructured":"Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S et al (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44:601\u2013607. https:\/\/doi.org\/10.1016\/j.neuron.2004.11.005","journal-title":"Neuron"}],"container-title":["Acta Neuropathologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-025-02872-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00401-025-02872-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-025-02872-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T14:02:44Z","timestamp":1746280964000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00401-025-02872-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,2]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["2872"],"URL":"https:\/\/doi.org\/10.1007\/s00401-025-02872-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.12.18.629265","asserted-by":"object"}]},"ISSN":["1432-0533"],"issn-type":[{"value":"1432-0533","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,2]]},"assertion":[{"value":"16 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Informed consent was obtained from the families of all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"42"}}